Filing Details
Barinthus Biotherapeutics plc. (NASDAQ:BRNS) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNASDAQ:BRNS
Barinthus Biotherapeutics plc. (BRNS) Reports Material Event to SEC
Filing Details Barinthus Biotherapeutics plc. (NASDAQ:BRNS) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market…
Market Context
Barinthus Biotherapeutics plc.'s stock currently trades at $0.62 with a market capitalization of $29.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Barinthus Biotherapeutics plc.'s stock.
All SEC filings for Barinthus Biotherapeutics plc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BRNS Stock Page
Frequently Asked Questions
Where can I read BRNS's SEC filings?
Browse all filings on our BRNS SEC filings page.
What types of SEC filings does Barinthus Biotherapeutics plc. file?
Public companies like Barinthus Biotherapeutics plc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.